Full-Time

Manager-Global CAPA System

CooperSurgical

CooperSurgical

1,001-5,000 employees

Provides reproductive health products and services

Compensation Overview

$120k - $170k/yr

Livingston, NJ, USA + 1 more

More locations: Bridgeport, CT, USA

In Person

Category
Biology & Biotech (1)
Required Skills
Veeva
Requirements
  • Demonstrated expertise in CAPA management, including root cause analysis, effectiveness checks, and lifecycle governance.
  • Strong working knowledge of global regulatory and quality standards including 21 CFR Part 820, 21 CFR Parts 210/211, ISO 13485, FDA Quality Management System Regulation, and EU Medical Device Regulation.
  • Experience supporting regulatory inspections, notified body audits, and internal quality audits, including CAPA-related observation remediation.
  • Proficiency with electronic Quality Management Systems and CAPA workflows (e.g., TrackWise, Veeva, MasterControl).
  • Proven ability to analyze quality data and trends to identify systemic issues and drive continuous improvement.
  • Proven ability to operate effectively within a matrixed global organization, influencing cross-functional teams.
  • Strong written and verbal communication skills, with the ability to influence cross-functional and global stakeholders.
  • Fluent English required; Spanish proficiency strongly preferred (or ability and willingness to quickly develop working proficiency).
  • Bachelor’s degree in Engineering, Life Sciences, Chemistry, or a related discipline required.
  • 8+ years of progressive quality experience in a regulated industry, with 3-5 years directly supporting or managing CAPA systems.
  • 5+ years of QA leadership experience with demonstrated ability to build, lead, and develop high-performing teams.
Responsibilities
  • Own and maintain the global CAPA program, including policies, procedures, workflows, and performance metrics.
  • Ensure alignment of CAPA processes with global regulatory requirements 21 CFR Part 820, 21 CFR Parts 210/211, ISO 13485, the FDA Quality Management System Regulation (QMSR), and the EU Medical Device Regulation (EU MDR).
  • Establish clear criteria for CAPA initiation, escalation, prioritization, effectiveness checks, and closure.
  • Serve as the global subject matter expert for CAPA-related regulatory expectations and best practices.
  • Lead, develop, and sustain high-performing global and site CAPA teams; set clear expectations, coach performance, and build deep technical expertise across sites in investigations, root cause analysis, CAPA effectiveness, and quality risk management.
  • Partner cross-functional with Quality, Regulatory Affairs, Manufacturing, R&D, Supply Chain, and Commercial teams to drive effective root cause analysis, ensure timely closure of CAPAs, and prevent recurrence of quality issues.
  • Oversee CAPA activities resulting from, but not limited to, deviations, nonconformances, audit and inspection findings, product complaints, adverse events, trend analyses, and risk management outputs.
  • Review and approve root cause analyses using structured methodologies (e.g., 5 Whys, Fishbone, Fault Tree, FMEA).
  • Ensure CAPA action plans are scientifically sound, data-driven, risk-based, and sustainable.
  • Monitor CAPA effectiveness and ensure verification of lasting corrective/preventive outcomes.
  • Develop and maintain global CAPA KPIs, dashboards, and management review inputs.
  • Perform trending and statistical analysis to identify systemic issues, recurring failures, or emerging risks.
  • Lead continuous improvement initiatives to reduce CAPA cycle time, improve quality maturity, and enhance inspection readiness.
  • Act as CAPA lead during regulatory inspections, notified body audits, and internal quality audits, including responses to observations and non-conformances.
  • Ensure inspection-ready documentation and clear traceability from issue identification through CAPA closure.
  • Support regulatory commitments and post-approval change management as applicable.
  • Develop and deliver CAPA training programs for global stakeholders.
  • Mentor site CAPA owners and quality teams to strengthen root cause analysis and problem-solving capabilities.
  • Represent the site and CooperSurgical in external forums (as assigned), including industry events, conventions, seminars, and trainings, maintaining professionalism and protecting company and product reputation.
  • Perform other duties as assigned.
Desired Qualifications
  • Master’s degree preferred.
  • Spanish proficiency strongly preferred.

What CooperSurgical does: CooperSurgical develops and provides products, technologies, and services that support women’s, babies’, and families’ health around the world. How its products work: The company offers a range of reproductive health solutions, including contraception, fertility support, and preventive and therapeutic gynecological care. These products assist clinicians and patients through devices, tests, and therapies designed to aid choice and care in reproductive health. How it differs from competitors: CooperSurgical focuses on a broad set of reproductive health needs—covering contraception, fertility, and gynecologic care—trusted by clinicians worldwide for a wide range of tools and services, which can enable more integrated care compared to providers focused on a narrower segment. Goal: To empower individuals and healthcare professionals to make informed health and life choices and improve care for women, babies, and families globally.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Trumbull, Connecticut

Founded

1990

Simplify Jobs

Simplify's Take

What believers are saying

  • Direct sales model strengthens customer relationships and improves data access in mature European markets.
  • Granata Bio investment positions CooperSurgical to capture emerging reproductive health biopharma innovations.
  • obp Surgical acquisition expands specialty surgery portfolio beyond women's health into adjacent surgical markets.

What critics are saying

  • Massachusetts lab quality control scandal triggers regulatory investigations into IVF product testing procedures.
  • European direct sales rollout faces reimbursement denials in France and Germany, limiting adoption.
  • obp Surgical integration stalls due to single-use retractor technology misalignment with existing portfolio.

What makes CooperSurgical unique

  • Direct-to-provider sales model in France, Italy, Germany, Spain eliminates distributor margins.
  • Integrated portfolio spans fertility, labor/delivery, and specialty surgery via obp and Zymōt acquisitions.
  • Proprietary sperm separation technology and single-hand IUD inserter reduce procedural complexity.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at CooperSurgical who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

Parental Leave

Fertility Treatment Support

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Company News

CooperSurgical
Feb 12th, 2026
CooperSurgical to Launch Direct Sales Model for Labor and Delivery Portfolio in Key European Markets

CooperSurgical to launch direct sales model for Labor and Delivery portfolio in key european markets. TRUMBULL, CT, December 11, 2025, CooperSurgical(R), a leader in women's healthcare and fertility solutions, today announced a strategic shift to a direct sales model for its premier Labor and Delivery products in France, Italy, Germany, and Spain. This transition will forge a closer relationship with healthcare providers, reinforcing the company's commitment to advancing the standard of care for women and babies. Beginning in the company's fiscal first quarter, healthcare providers and healthcare facilities in these markets will gain the ability to procure products directly from CooperSurgical. The portfolio includes the vacuum-assisted delivery products, Fetal Pillow(TM) cephalic elevation device, the INSORB(R) subcuticular skin stapler, and the Lone Star(R) retractor system. This change from a distributor-led model is designed to streamline the customer's ordering process, facilitate easier access to these critical technologies, and provide direct support from CooperSurgical's dedicated customer care center. By creating a direct channel, CooperSurgical aims to better support the clinical community, ensuring that physicians have the resources and guidance needed to implement these innovative solutions effectively. This initiative is central to the company's mission of delivering technologies that support healthier families. About CooperSurgical CooperSurgical is a leading company dedicated to advancing the health of women, babies, and families. The company's portfolio offers effective solutions that support clinical efficiency from conception to delivery. With a history of innovation in the fertility and women's health field, CooperSurgical has pioneered new technologies and continues to drive progress in the industry. Existing Customers - Order directly from CooperSurgical Previously purchased through a distributor? CooperSurgical, Inc. has simplified the process. Its dedicated sales team can assist with product availability, pricing, ordering, and delivery information specific to your country

PR Newswire
Mar 10th, 2025
2025 Inception Fertility Physician Summit Brings Together Thought Leaders, Researchers, And Clinicians From Across The Company To Celebrate Patient Dedication, Collaborate On Research, And Discuss The Future Of Fertility Care

North America's largest provider of fertility services collaborates, celebrates achievements in fertility care including unparalleled patient services. HOUSTON, March 10, 2025 /PRNewswire/ -- Inception Fertility™ (Inception), North America's largest provider of comprehensive fertility services, held its Annual Inception Physician Summit in Nashville, Tennessee, February 22-25, 2024. The Summit brings together team members, including reproductive specialists and clinical managers, from across Inception's vast network of global fertility clinics, The Prelude Network®, to share best practices and resources that make each clinic a leading fertility provider in their respective markets

FinSMEs
Jan 15th, 2025
Granata Bio Secures $15M Series A+ Funding

Granata Bio Corporation, a biopharma company in Boston, MA, raised $15 million in Series A+ funding. Investors included Gedeon Richter, CooperSurgical, and Amboy Street Ventures. The funds will support the company's pipeline and exploration of new assets in reproductive health. Granata Bio has raised over $30 million to date.

Daily Journal
Oct 9th, 2024
Toxic embryo culture lawsuits allowed to proceed

Four plaintiffs have filed separate lawsuits against CooperSurgical Inc., accusing the company of selling defective embryo culture which caused embryos to die.

Medical Device Network
Sep 4th, 2024
CooperSurgical introduces single-hand inserter for Paragard IUD

CooperSurgical has introduced a new single-hand inserter for the Paragard copper intrauterine device (IUD).